Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! By

Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity Publisher Pubmed

N Safaie NASSER ; G Idari GHOLAMREZA ; D Ghasemi DIBA ; M Hajiabbasi MOBASHER ; V Alivirdiloo VAHID ; S Masoumi SHAHAB ; M Zavvar MAHDI ; Z Majidi ZIBA ; Y Faridvand YOUSEF

Source: Archives of Physiology and Biochemistry Published:2025

Abstract

The introduction of Tyrosine Kinase Inhibitors (TKIs) has revolutionised cancer treatment, yet concerns regarding cardiovascular toxicity have surfaced. This piece delves into the interplay between AMP-activated protein kinase (AMPK) signalling and TKI-induced cardiovascular toxicity. The study unravels the intricate relationship between AMPK activation and TKI-induced cardiovascular toxicity, aiming to ascertain whether AMPK can play a strategic role in mitigating adverse effects. Beyond unravelling mechanistic insights, the research sets the stage for future therapeutic approaches, envisioning AMPK activation as a pivotal connection for balancing effective cancer treatment with cardiovascular well-being. As research advances, the potential of AMPK activation not only addresses challenges in TKI-induced cardiovascular toxicity but also shapes the future landscape of personalised anticancer therapies. The article explores the mechanisms of TKI-induced toxicity, AMPK’s impact on cardiovascular health, and the potential therapeutic implications of AMPK activation in alleviating TKI-associated toxicities. © 2025 Elsevier B.V., All rights reserved.

Related Docs

View other Related Docs

1. Lkb1: An Emerging Therapeutic Target for Cardiovascular Diseases, Life Sciences (2022)

2. Looking Into the Toxicity Potential and Clinical Benefits of Tyrosine Kinase Inhibitors (Tkis), Encyclopedia of Toxicology# Fourth Edition: Volume 1-9 (2023)

3. Nf-Κb As the Main Node of Resistance to Receptor Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer, Tumor Biology (2017)

Experts (# of related papers)

View all Related Experts

Mohammad Hossein Yazdi (2)

Shekoufeh Nikfar (1)

Other Related Docs

4. Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment, Cardiovascular Toxicology (2024)

5. Empagliflozin Treatment of Cardiotoxicity: A Comprehensive Review of Clinical, Immunobiological, Neuroimmune, and Therapeutic Implications, Biomedicine and Pharmacotherapy (2023)

6. Comparative Safety and Efficacy of Tyrosine Kinase Inhibitors (Tkis) in the Treatment Setting of Different Types of Leukemia, and Different Types of Adenocarcinoma, Biomedicine and Pharmacotherapy (2017)

7. Ampk’S Double-Faced Role in Advanced Stages of Prostate Cancer, Clinical and Translational Oncology (2022)

8. Risk Pathway Is Involved in Oxytocin Postconditioning in Isolated Rat Heart, Peptides (2016)

9. Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy, Cancer Treatment and Research Communications (2022)

10. Natural Activators of Adenosine 5′-Monophosphate (Amp)-Activated Protein Kinase (Ampk) and Their Pharmacological Activities, Food and Chemical Toxicology (2018)

11. Doxorubicin-Related Cardiotoxicity: Review of Fundamental Pathways of Cardiovascular System Injury, Cardiovascular Pathology (2024)

12. The Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Chemotherapy-Induced Cardiotoxicity and Mortality in Patients With Cancer: A Systematic Review and Meta-Analysis, Cardio-Oncology (2025)

13. Non-Coding Rnas As Potential Therapeutic Targets for Receptor Tyrosine Kinase Signaling in Solid Tumors: Current Status and Future Directions, Cancer Cell International (2024)

Style	Citing Format
MLA	N Safaie NASSER, et al.. "Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity." Archives of Physiology and Biochemistry, vol. 131, no. 3, 2025, pp. 329-341.
APA	N Safaie NASSER, G Idari GHOLAMREZA, D Ghasemi DIBA, M Hajiabbasi MOBASHER, V Alivirdiloo VAHID, S Masoumi SHAHAB, M Zavvar MAHDI, Z Majidi ZIBA, Y Faridvand YOUSEF (2025). Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity. Archives of Physiology and Biochemistry, 131(3), 329-341.
Chicago	N Safaie NASSER, G Idari GHOLAMREZA, D Ghasemi DIBA, M Hajiabbasi MOBASHER, V Alivirdiloo VAHID, S Masoumi SHAHAB, M Zavvar MAHDI, Z Majidi ZIBA, Y Faridvand YOUSEF. "Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity." Archives of Physiology and Biochemistry 131, no. 3 (2025): 329-341.
Harvard	N Safaie NASSER et al. (2025) 'Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity', Archives of Physiology and Biochemistry, 131(3), pp. 329-341.
Vancouver	N Safaie NASSER, G Idari GHOLAMREZA, D Ghasemi DIBA, M Hajiabbasi MOBASHER, V Alivirdiloo VAHID, S Masoumi SHAHAB, et al.. Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity. Archives of Physiology and Biochemistry. 2025;131(3):329-341.
BibTex	@article{ author = {N Safaie NASSER and G Idari GHOLAMREZA and D Ghasemi DIBA and M Hajiabbasi MOBASHER and V Alivirdiloo VAHID and S Masoumi SHAHAB and M Zavvar MAHDI and Z Majidi ZIBA and Y Faridvand YOUSEF}, title = {Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity}, journal = {Archives of Physiology and Biochemistry}, volume = {131}, number = {3}, pages = {329-341}, year = {2025} }
RIS	TY - JOUR AU - N Safaie NASSER AU - G Idari GHOLAMREZA AU - D Ghasemi DIBA AU - M Hajiabbasi MOBASHER AU - V Alivirdiloo VAHID AU - S Masoumi SHAHAB AU - M Zavvar MAHDI AU - Z Majidi ZIBA AU - Y Faridvand YOUSEF TI - Ampk Activation; a Potential Strategy to Mitigate Tki-Induced Cardiovascular Toxicity JO - Archives of Physiology and Biochemistry VL - 131 IS - 3 SP - 329 EP - 341 PY - 2025 ER -

Science Communicator Platform

Authors

Abstract